Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
infliximab + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a combination of two drugs: - **Infliximab** is a chimeric monoclonal IgG1 antibody that targets and neutralizes tumor necrosis factor alpha (TNF-α), a key proinflammatory cytokine involved in chronic inflammatory diseases. By binding to both soluble and membrane-bound TNF-α, infliximab disrupts its interaction with receptors and may induce lysis of TNF-α-producing cells. It is primarily used for autoimmune conditions such as rheumatoid arthritis and Crohn's disease[1]. - **Gemcitabine** is a nucleoside analog antimetabolite chemotherapeutic agent. As a prodrug metabolized intracellularly to active diphosphate and triphosphate forms (dFdCDP/dFdCTP), it incorporates into DNA during replication causing chain termination and apoptosis in rapidly dividing cells. It is used for various cancers including pancreatic cancer (as monotherapy) as well as ovarian cancer (with carboplatin), breast cancer (with paclitaxel), non-small cell lung carcinoma (with cisplatin), among others[2][4].
- Brand names
- FlixabiZessly
- Other names
- chimeric monoclonal anti-TNF-alpha antibodydFdCdifluorodeoxycytidine2’,2’-difluorodeoxycytidineLY 188011LY188011LY-188011
02
Targets
DNADNA polymerase familyTNFA (Tumor necrosis factor alpha (soluble))RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on infliximab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on infliximab + gemcitabine.